Nasdaq
$14.42▲ 0.17%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $2.51BShares out 1.700M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
10- 4d agoPre-market26.10.21 19:036-KKey event#●●●#●●●#●●●
HUTCHMED (China) LtdBullish
HUTCHMED has officially closed its exclusive development and license agreement with GSK for the KRAS-EGFR antibody-targeted therapy conjugate, HMPL-A830. Under the terms, HUTCHMED will receive an upfront payment of $110 million and is eligible for up to $1.185 billion in additional development, regulatory, and commercial milestone payments, plus tiered royalties.…more
$14.42+0.17%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.29Pre-market26.09.29 19:036-KKey event
HUTCHMED (China) Ltd
HUTCHMED announced that AstraZeneca has submitted a New Drug Application (NDA) to the US FDA for the combination of ORPATHYS and TAGRISSO. This filing targets patients with MET-driven EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy, supported by positive results from the global Phase III SAFFRON trial.…more
$14.42+0.17%vs prev closeView filingShare - 9.29Pre-market26.09.29 10:26filed6-KKey event
HUTCHMED (China) Ltd
HUTCHMED has initiated the Phase Ia global clinical trial for its solid tumor drug candidate HMPL-A830, with the first patient dosed in China on September 24, 2026. Additionally, the company entered into an exclusive development and license agreement with GSK on September 3, 2026, granting GSK rights to develop and commercialize HMPL-A830 outside of Greater China.…more
$14.42+0.17%vs prev closeView filingShare
9 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 4d agoOvernight26.10.21 16:34Bullish#●●●#●●●
HUTCHMED Finalizes Exclusive Licensing Deal with GSK for KRAS-EGFR Inhibitor…more
HUTCHMED has closed an exclusive licensing agreement with GSK for its KRAS-EGFR inhibitor outside of China. The deal includes an upfront payment of $110 million and potential milestone payments reaching up to $1.185 billion.…more
$14.42+0.17%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 4d agoOvernight26.10.21 09:00
●●●●●●●● ●●●●● ●●●●●●
HUTCHMED has finalized an exclusive licensing agreement with GSK for its cancer drug candidate HMPL-A830. The deal includes an upfront payment of $110 million and potential milestone payments of up to $1.185 billion, plus tiered royalties.…more
$14.42+0.17%vs prev close - 9.29Pre-market26.09.29 17:29
●●●●●●●● ●●●●● ●●●●●●
HUTCHMED reported that AstraZeneca has submitted a US NDA for the combination of ORPATHYS and TAGRISSO to treat specific lung cancer patients. The application is supported by positive data from the Phase III SAFFRON trial demonstrating improved survival outcomes.…more
$14.42+0.17%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report